{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T23:07:29Z","timestamp":1769728049096,"version":"3.49.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T00:00:00Z","timestamp":1520812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s11255-018-1838-5","type":"journal-article","created":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T16:50:22Z","timestamp":1520873422000},"page":"1271-1275","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Calcimimetics versus parathyroidectomy: What is preferable?"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1048-2579","authenticated-orcid":false,"given":"M.","family":"Rroji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Spasovski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,12]]},"reference":[{"issue":"11","key":"1838_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Dr\u00fceke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G (2006) Kidney disease: improving global outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69(11):1945\u20131953","journal-title":"Kidney Int"},{"key":"1838_CR2","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1053\/j.ajkd.2003.12.004","volume":"43","author":"J Cunningham","year":"2004","unstructured":"Cunningham J, Sprague SM, Cannata-Andia J, Coco M, Cohen-Solal M, Fitzpatrick L, Goltzmann D, Lafage-Proust MH, Leonard M, Ott S, Rodriguez M, Stehman-Breen C, Stern P, Weisinger J, Osteoporosis Work Group (2004) Osteoporosis in chronic kidney disease. Am J Kidney Dis 43:566\u2013571","journal-title":"Am J Kidney Dis"},{"key":"1838_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ki.2012.69","volume":"82","author":"PA Torres","year":"2012","unstructured":"Torres PA, De Broe M (2012) Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease. Kidney Int 82:19\u201325","journal-title":"Kidney Int"},{"key":"1838_CR4","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM et al (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208\u20132218","journal-title":"J Am Soc Nephrol"},{"key":"1838_CR5","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","volume":"12","author":"SK Ganesh","year":"2001","unstructured":"Ganesh SK, Stack AG, Levin NW et al (2001) Association of elevated serum PO(4), Ca\u2009\u00d7\u2009PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131\u20132138","journal-title":"J Am Soc Nephrol"},{"key":"1838_CR6","unstructured":"KDIGO (2012) Clinical practice guideline for the evaluation and management of chronic kidney disease, vol 3(1), pp 1\u2013150, January 2013"},{"key":"1838_CR7","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1053\/j.ajkd.2010.02.340","volume":"55","author":"K Uhlig","year":"2010","unstructured":"Uhlig K, Berns JS, Kestenbaum B et al (2010) KDOQI U.S. commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Am J Kidney Dis 55:773\u2013799","journal-title":"Am J Kidney Dis"},{"key":"1838_CR8","first-page":"S1","volume":"42","author":"National Kidney Foundation","year":"2003","unstructured":"National Kidney Foundation (2003) K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:S1","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1838_CR9","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1046\/j.1523-1755.2000.00183.x","volume":"58","author":"WG Goodman","year":"2000","unstructured":"Goodman WG, Frazao JM, Goodkin DA et al (2000) A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58(1):436\u2013445","journal-title":"Kidney Int"},{"key":"1838_CR10","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1093\/ndt\/13.8.1923","volume":"13","author":"EF Nemeth","year":"1998","unstructured":"Nemeth EF, Bennett SA (1998) Tricking the parathyroid gland with novel calcimimetic agents. Nephrol Dial Transpl 13:1923\u20131925","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"1838_CR11","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/j.1523-1755.2005.67139.x","volume":"67","author":"SM Moe","year":"2005","unstructured":"Moe SM, Chertow GM, Coburn JW et al (2005) Achieving NKF-K\/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67(2):760\u2013771","journal-title":"Kidney Int"},{"issue":"1","key":"1838_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2215\/CJN.03591006","volume":"3","author":"P Messa","year":"2008","unstructured":"Messa P, Mac\u00e1rio F, Yaqoob M et al (2008) The OPTIMA study: assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 3(1):36\u201345","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"1838_CR13","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.2215\/CJN.06141108","volume":"4","author":"SM Sprague","year":"2009","unstructured":"Sprague SM, Evenepoel P, Curzi MP et al (2009) Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol 4(9):1465\u20131476","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"1838_CR14","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/ndt\/gfl840","volume":"22","author":"MD Arenas","year":"2007","unstructured":"Arenas MD, Alvarez-Ude F, Gil MT et al (2007) Implementation of \u2018K\/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease\u2019 after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transpl 22(6):1639\u20131644","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"1838_CR15","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.2215\/CJN.01040308","volume":"3","author":"S Fishbane","year":"2008","unstructured":"Fishbane S, Shapiro WB, Corry DB et al (2008) Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 3(6):1718\u20131725","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1838_CR16","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/ndt\/gfs568","volume":"28","author":"P Urena-Torres","year":"2013","unstructured":"Urena-Torres P, Bridges I, Christiano C et al (2013) Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. Nephrol Dial Transpl 28(5):1241\u20131254","journal-title":"Nephrol Dial Transpl"},{"key":"1838_CR17","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/ki.2014.349","volume":"87","author":"GJ Behets","year":"2015","unstructured":"Behets GJ, Spasovski G, D\u2019Haese PC et al (2015) Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int 87:846\u2013856","journal-title":"Kidney Int"},{"key":"1838_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","volume":"92","author":"M Ketteler","year":"2017","unstructured":"Ketteler M, Block GA, Evenepoel P et al (2017) Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (ckd-mbd) guideline update: what\u2019s changed and why it matters. Kidney Int 92:26\u201336","journal-title":"Kidney Int"},{"key":"1838_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd006023.pub2","author":"SD Navaneethan","year":"2011","unstructured":"Navaneethan SD, Palmer SC, Vecchio M et al (2011) Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.cd006023.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"1838_CR20","doi-asserted-by":"publisher","first-page":"840","DOI":"10.7326\/0003-4819-147-12-200712180-00004","volume":"147","author":"SC Palmer","year":"2007","unstructured":"Palmer SC, McGregor DO, Macaskill P et al (2007) Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 147(12):840\u2013853","journal-title":"Ann Intern Med"},{"issue":"26","key":"1838_CR21","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"EVOLVE Trial Investigators","year":"2012","unstructured":"Trial Investigators EVOLVE, Chertow GM, Block GA, Parfrey PS et al (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367(26):2482\u20132494","journal-title":"N Engl J Med"},{"issue":"1","key":"1838_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/nrneph.2012.258","volume":"9","author":"EF Carney","year":"2013","unstructured":"Carney EF (2013) Chronic kidney disease: no significant effect of cinacalcet on cardiovascular outcomes in patients undergoing dialysis\u2013EVOLVE results. Nat Rev Nephrol 9(1):4. https:\/\/doi.org\/10.1038\/nrneph.2012.258 (Epub 2012 Nov 20)","journal-title":"Nat Rev Nephrol"},{"issue":"7","key":"1838_CR23","first-page":"348","volume":"71","author":"MG Vervloet","year":"2013","unstructured":"Vervloet MG, du Buf-Vereijken PW, Potter van Loon BJ et al (2013) Cinacalcet for secondary hyperparathyroidism: from improved mineral levels to improved mortality? Neth J Med 71(7):348\u2013354","journal-title":"Neth J Med"},{"key":"1838_CR24","unstructured":"Locatelli F, Messa P, Bellasi A et al (2013) What can we learn from a statistically inconclusive trial? Consensus conference on the EVOLVE study results. G Ital Nefrol 30(5):pii:gin\/30.5.4"},{"issue":"6","key":"1838_CR25","doi-asserted-by":"publisher","first-page":"e001363","DOI":"10.1161\/JAHA.114.001363","volume":"3","author":"DC Wheeler","year":"2014","unstructured":"Wheeler DC et al (2014) Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. J Am Heart Assoc 3(6):e001363. https:\/\/doi.org\/10.1161\/jaha.114.001363","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"1838_CR26","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.jval.2015.08.007","volume":"18","author":"V Belozeroff","year":"2015","unstructured":"Belozeroff V, Chertow GM, Graham CN (2015) Economic evaluation of cinacalcet in the United States: the EVOLVE trial. Value Health 18(8):1079\u20131087","journal-title":"Value Health"},{"issue":"5","key":"1838_CR27","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/kisup.2013.91","volume":"3","author":"Sh Fukuma","year":"2013","unstructured":"Fukuma Sh, Akizawa T, Fukuhara Sh et al (2013) Impact of cinacalcet introduction on MBD management: the MBD-5D study in Japan. Kidney Int Suppl (2011) 3(5):436\u2013441","journal-title":"Kidney Int Suppl (2011)"},{"key":"1838_CR28","doi-asserted-by":"publisher","first-page":"19612","DOI":"10.1038\/srep19612","volume":"6","author":"T Akizawa","year":"2016","unstructured":"Akizawa T, Kurita N, Fukuhara Sh (2016) PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Sci Rep 6:19612","journal-title":"Sci Rep"},{"issue":"10","key":"1838_CR29","doi-asserted-by":"publisher","first-page":"e0164865","DOI":"10.1371\/journal.pone.0164865","volume":"11","author":"M Tanaka","year":"2016","unstructured":"Tanaka M, Yoshida K, Fukagawa M et al (2016) Effects of secondary hyperparathyroidism treatment on improvement in anemia: results from the MBD-5D study. PLoS ONE 11(10):e0164865. https:\/\/doi.org\/10.1371\/journal.pone.0164865","journal-title":"PLoS ONE"},{"key":"1838_CR30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejim.2017.05.002","volume":"42","author":"C Friedl","year":"2017","unstructured":"Friedl C, Reibnegger G, Kramar R (2017) Mortality in dialysis patients with cinacalcet use: a large observational registry study. Eur J Intern Med 42:89\u201395","journal-title":"Eur J Intern Med"},{"issue":"4","key":"1838_CR31","doi-asserted-by":"publisher","first-page":"e1001436","DOI":"10.1371\/journal.pmed.1001436","volume":"10","author":"SC Palmer","year":"2013","unstructured":"Palmer SC, Stripoli Nistor I et al (2013) Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med 10(4):e1001436","journal-title":"PLoS Med"},{"key":"1838_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/14651858","author":"AE Ballinger","year":"2014","unstructured":"Ballinger AE, Palmer SC, Nistor I et al (2014) Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1838_CR33","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/ndt\/gfv050","volume":"30","author":"D Goldsmith","year":"2015","unstructured":"Goldsmith D, Covic A, Vervloet M, Cozzolino M, Nistor I (2015) Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) working group and the European Renal Best Practice (ERBP) advisory board; should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrol Dial Transpl 30(5):698\u2013700","journal-title":"Nephrol Dial Transpl"},{"issue":"Suppl 1","key":"1838_CR34","first-page":"5","volume":"6","author":"W Fassbinder","year":"1991","unstructured":"Fassbinder W, Brunner FP et al (1991) Combined report on regular dialysis and transplantation in Europe. Nephrol Dial Transpl 6(Suppl 1):5\u201335","journal-title":"Nephrol Dial Transpl"},{"key":"1838_CR35","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1007\/s00268-001-0019-2","volume":"25","author":"PA Decker","year":"2001","unstructured":"Decker PA, Cohen EP, Ashley ME et al (2001) Subtotal parathyroidectomy in renal failure: still needed after all these years. World J Surg 25:708\u2013712","journal-title":"World J Surg"},{"key":"1838_CR36","first-page":"S92","volume":"13","author":"MG Esposito","year":"2008","unstructured":"Esposito MG, Cesare CM, De Santo RM et al (2008) Parathyroidectomy improves the quality of sleep in maintenance hemodialysis patients with severe hyperparathyroidism. J Nephrol Suppl 13:S92\u2013S96","journal-title":"J Nephrol Suppl"},{"issue":"3","key":"1838_CR37","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s12020-012-9648-5","volume":"42","author":"G Conzo","year":"2012","unstructured":"Conzo G, Perna A, Avenia N et al (2012) Evaluation of \u201cputative\u201d role of intraoperative intact parathyroid hormone assay during parathyroidectomy for secondary hyperparathyroidism. A retrospective study on 35 consecutive patients. Endocrine 42(3):606\u2013611","journal-title":"Endocrine"},{"key":"1838_CR38","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/j.ajkd.2005.04.035","volume":"46","author":"AJ Bleyer","year":"2005","unstructured":"Bleyer AJ, Burkart J, Piazza M et al (2005) Changes in cardiovascular calcification after parathyroidectomy in patients with ESRD. Am J Kidney Dis 46:464\u2013469","journal-title":"Am J Kidney Dis"},{"key":"1838_CR39","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0272-6386(96)90519-3","volume":"27","author":"DJ Goldsmith","year":"1996","unstructured":"Goldsmith DJ, Covic AA, Venning MC et al (1996) Blood pressure reduction after parathyroidectomy for secondary hyperparathyroidism: further evidence implicating calcium homeostasis in blood pressure regulation. Am J Kidney Dis 27:819\u2013825","journal-title":"Am J Kidney Dis"},{"key":"1838_CR40","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1093\/ndt\/gfh892","volume":"20","author":"P Evenepoel","year":"2005","unstructured":"Evenepoel P, Claes K, Kuypers D et al (2005) Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. Nephrol Dial Transpl 20:1714\u20131720","journal-title":"Nephrol Dial Transpl"},{"key":"1838_CR41","first-page":"172","volume":"52","author":"MS Stein","year":"1999","unstructured":"Stein MS, Packham DK, Wark JD et al (1999) Response to parathyroidectomy at the axial and appendicular skeleton in renal patients. Clin Nephrol 52:172\u2013178","journal-title":"Clin Nephrol"},{"key":"1838_CR42","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/archsurg.143.8.756","volume":"143","author":"N Rayes","year":"2008","unstructured":"Rayes N, Seehofer D, Schindler R et al (2008) Long-term results of subtotal vs total parathyroidectomy without autotransplantation in kidney transplant recipients. Arch Surg 143:756\u2013761","journal-title":"Arch Surg"},{"issue":"Supplement 85\u00a0","key":"1838_CR43","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1046\/j.1523-1755.63.s85.23.x","volume":"63","author":"R Jofre","year":"2003","unstructured":"Jofre R, Lopez Gomez JM, Menarguez J et al (2003) Parathyroidectomy: whom and when? Kidney Int 63(Supplement 85\u00a0):S97\u2013S100","journal-title":"Kidney Int"},{"key":"1838_CR44","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/hed.21757","volume":"34","author":"PK Gupta","year":"2012","unstructured":"Gupta PK, Smith RB, Gupta H et al (2012) Outcomes after thyroidectomy and parathyroidectomy. Head Neck 34:477\u2013484","journal-title":"Head Neck"},{"issue":"6","key":"1838_CR45","doi-asserted-by":"publisher","first-page":"e0156863","DOI":"10.1371\/journal.pone.0156863","volume":"11","author":"Y-H Hsu","year":"2016","unstructured":"Hsu Y-H, Yu H-I, Kao C-H et al (2016) The risk of peripheral arterial disease after parathyroidectomy in patients with end-stage renal disease. PLoS ONE 11(6):e0156863. https:\/\/doi.org\/10.1371\/journal.pone.0156863","journal-title":"PLoS ONE"},{"key":"1838_CR46","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1093\/ndt\/gfv334","volume":"30","author":"KM Ivarsson","year":"2015","unstructured":"Ivarsson KM, Akaberi Sh, Isaksson E et al (2015) The effect of parathyroidectomy on patient survival in secondary hyperparathyroidism. Nephrol Dial Transpl 30:2027\u20132033","journal-title":"Nephrol Dial Transpl"},{"key":"1838_CR47","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1523-1755.2004.00368.x","volume":"65","author":"B Kestenbaum","year":"2004","unstructured":"Kestenbaum B, Seliger SL, Gillen DL et al (2004) Parathyroidectomy rates among United States dialysis patients: 1990\u20131999. Kidney Int 65:282\u2013288","journal-title":"Kidney Int"},{"key":"1838_CR48","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/ki.2015.72","volume":"88","author":"H Komaba","year":"2015","unstructured":"Komaba H, Taniguchi M, Wada A et al (2015) Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 88:350\u2013359","journal-title":"Kidney Int"},{"key":"1838_CR49","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jamcollsurg.2011.12.046","volume":"214","author":"J Sharma","year":"2012","unstructured":"Sharma J, Raggi P, Kutner N et al (2012) Improved long-term survival of dialysis patients after near-total parathyroidectomy. J Am Coll Surg 214:400\u2013407","journal-title":"J Am Coll Surg"},{"issue":"Suppl 2","key":"1838_CR50","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/1471-2482-13-S2-S4","volume":"13","author":"G Conzo","year":"2013","unstructured":"Conzo G, Perna A, Savica S et al (2013) Impact of parathyroidectomy on cardiovascular outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cases prior to calcimimetics era. BMC Surg 13(Suppl 2):S4. https:\/\/doi.org\/10.1186\/1471-2482-13-s2-s4","journal-title":"BMC Surg"},{"issue":"11","key":"1838_CR51","doi-asserted-by":"publisher","first-page":"e0187025","DOI":"10.1371\/journal.pone.0187025","volume":"12","author":"M Apetrii","year":"2017","unstructured":"Apetrii M, Goldsmith D, Covic A et al (2017) Impact of surgical parathyroidectomy on chronic kidney disease-mineral and bone disorder (CKD-MBD)\u2014a systematic review and meta-analysis. PLoS ONE 12(11):e0187025. https:\/\/doi.org\/10.1371\/journal.pone.018702552","journal-title":"PLoS ONE"},{"issue":"11","key":"1838_CR52","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1093\/ndt\/gfx044","volume":"32","author":"WY Plas van der","year":"2017","unstructured":"van der Plas WY, Dulfer RR, Engelsman AF et al (2017) Effect of parathyroidectomy and cinacalcet on quality of life in patients with end-stage renal disease-related hyperparathyroidism: a systematic review. Nephrol Dial Transpl 32(11):1902\u20131908","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"1838_CR53","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2215\/CJN.06370615","volume":"11","author":"PS Parfrey","year":"2016","unstructured":"Parfrey PS, Block G, Chertow G et al (2016) Lessons learned from EVOLVE for planning of future randomized trials in patients on dialysis. Clin J Am Soc Nephrol 11(3):539\u2013546","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-018-1838-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-018-1838-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-018-1838-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T21:57:10Z","timestamp":1660600630000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-018-1838-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,12]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["1838"],"URL":"https:\/\/doi.org\/10.1007\/s11255-018-1838-5","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,12]]},"assertion":[{"value":"26 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}